Legal Representation
Attorney
Tara L. Allstun
USPTO Deadlines
Application History
29 eventsDate | Code | Type | Description |
---|---|---|---|
Dec 16, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
Dec 16, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
May 17, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
May 16, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
May 16, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
May 16, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
Oct 19, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Oct 17, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED |
Oct 17, 2023 | EXT1 | S | SOU EXTENSION 1 FILED |
Oct 17, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
May 16, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Mar 21, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Mar 21, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
Mar 1, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Feb 13, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jan 30, 2023 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
May 31, 2022 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
Oct 26, 2021 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Oct 26, 2021 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
Oct 26, 2021 | CNSL | R | SUSPENSION LETTER WRITTEN |
Oct 4, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Oct 4, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Oct 4, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Sep 14, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Sep 14, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED |
Sep 14, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
Sep 10, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
May 18, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Feb 18, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for treatment of neurological and cardiovascular diseases
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"